mTOR pathway inhibitors in cancer therapy: moving past rapamycin

Pharmacogenomics. 2010 Sep;11(9):1189-91. doi: 10.2217/pgs.10.113.
No abstract available

Publication types

  • Comparative Study
  • Editorial

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Clinical Trials as Topic
  • Humans
  • Mammals
  • Mechanistic Target of Rapamycin Complex 1
  • Multiprotein Complexes
  • Neoplasms / drug therapy*
  • Neoplasms / enzymology*
  • Phosphoinositide-3 Kinase Inhibitors
  • Phosphorylation / drug effects
  • Protein Kinase Inhibitors / therapeutic use*
  • Protein Kinases / metabolism
  • Proteins / antagonists & inhibitors
  • Proto-Oncogene Proteins c-akt / antagonists & inhibitors
  • Signal Transduction / drug effects
  • Sirolimus / analogs & derivatives
  • Sirolimus / pharmacology
  • Sirolimus / therapeutic use*
  • TOR Serine-Threonine Kinases / antagonists & inhibitors*
  • TOR Serine-Threonine Kinases / metabolism
  • Transcription Factors / antagonists & inhibitors

Substances

  • Antineoplastic Agents
  • CRTC2 protein, human
  • Multiprotein Complexes
  • Phosphoinositide-3 Kinase Inhibitors
  • Protein Kinase Inhibitors
  • Proteins
  • Transcription Factors
  • Protein Kinases
  • MTOR protein, human
  • Mechanistic Target of Rapamycin Complex 1
  • Proto-Oncogene Proteins c-akt
  • TOR Serine-Threonine Kinases
  • Sirolimus